Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mixed salts of a single-entity amphetamine product extended-release capsules
- Development stage
- Phase 4
- Lead developer
- Granules Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mixed salts of a single-entity amphetamine product extended-release capsules (commonly referred to by the brand name Adderall XR) is a central nervous system (CNS) stimulant formulation containing a 3:1 mixture of dextroamphetamine and levoamphetamine salts (specifically dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate). Developed as a once-daily extended-release treatment, it is widely approved for the treatment of attention deficit hyperactivity disorder (ADHD). The drug works by increasing the extracellular levels of the neurotransmitters dopamine and norepinephrine in the synaptic cleft. It achieves this primarily by binding to and reversing the transport of the sodium-dependent dopamine transporter (DAT) and sodium-dependent noradrenaline transporter (NET), as well as acting as an agonist at the trace amine-associated receptor 1 (TAAR1) and inhibiting the vesicular monoamine transporter 2 (VMAT2).
- Brand names
- Adderall XR
- Other names
- amphetamine aspartate monohydrate + amphetamine sulfate + dextroamphetamine saccharate + dextroamphetamine sulfateamphetamine/dextroamphetamine extended-release capsulesmixed salts of a single entity amphetamine product extended-release capsules
02
Targets
NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)TAAR1 (Trace amine-associated receptor 1)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on mixed salts of a single-entity amphetamine product extended-release capsules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mixed salts of a single-entity amphetamine product extended-release capsules.